Equillium, Inc.

NASDAQ:EQ

Biotechnology

Healthcare
$1.10 +1.51%

+$0.05 today

Market cap
$90.56M
Beta
1.76
P/E (TTM)
-15.3
EPS (TTM)
-$0.20
52W Low $0.27High $3.45

Volume 0.89M

Average 0.60M

EQ Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Equillium, Inc.NASDAQ: EQ

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 96.28M shares rose 170.5% year over year, ahead of the +81.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at +39.7% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +170.5% holds above the trailing-twelve-month pace of +81.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
96.28M+4.8% QoQ
Last fiscal yearDec 2025
91.88M+159.9% YoY
LTMMar 2026
64.9M+81.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+170.5%——
1 year+159.9%——
3-year CAGR+39.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
91.88M USD
Year-over-year change
+159.9%
4-year CAGR
+33.6%

Weighted Avg Shares (Diluted) vs competitors

How EQ compares with its peers on the latest reported figures

  • EQ's LTM Mar 2026 weighted avg shares (diluted) of 64.9M shares is the 3rd highest of the 10 companies compared; the peer median is 28.35M shares.
  • Its year-over-year change of +81.6% is the 3rd highest of 10, against a peer median of +14.4%.
  • Over three fiscal years its annual growth of +39.7% compares with a peer median of +8.2%.
EQ Competitors Peer median
Weighted Avg Shares (Diluted) for EQ and competitors
Company Period LTM YoY 3-year CAGR
FBIOFortress Biotech, Inc.LTM Mar 202695.09M +349.0%+261.1%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +81.6%+39.7%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 202632.45M +9.5%+2.2%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.76M +80.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding EQ) 28.35M+14.4%+8.2%

Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015.76M36.08M41.1M0
Cost of Revenue0000116K
Gross Profit015.76M36.08M41.1M(116K)
Gross Margin—100.0%100.0%100.0%—
Research & Development26.38M37.55M37.04M37.43M12.84M
Selling, General & Admin11.41M17.24M13.57M11.94M10.79M
Operating Expenses37.79M77.84M50.61M49.36M23.63M
Depreciation & Amortization72K118K126K137K116K
EBITDA(37.91M)(61.26M)(12.14M)(7.57M)(22.28M)
EBITDA Margin—-388.7%-33.6%-18.4%—
Operating Income(37.79M)(62.08M)(14.52M)(8.27M)(23.63M)
Operating Margin—-393.9%-40.2%-20.1%—
Interest Income57K420K2.33M1.38M833K
Interest Expense1.07M1.05M491K00
Other Income / Expenses(1.27M)(352K)1.77M563K1.24M
Income Before Tax(39.05M)(62.43M)(12.76M)(7.71M)(22.4M)
Pre-Tax Margin—-396.1%-35.3%-18.8%—
Income Tax Expense00580K361K0
Net Income(38.98M)(62.43M)(13.34M)(8.07M)(22.4M)
Net Margin—-396.1%-37.0%-19.6%—
EPS (Basic)(1.35)(3.19)(0.38)(0.23)(0.39)
EPS (Diluted)(1.35)(3.19)(0.38)(0.23)(0.39)
Weighted Avg Shares28.81M33.73M34.73M35.36M91.88M
Weighted Avg Shares (Diluted)28.81M33.73M34.73M35.36M91.88M

Equillium, Inc.

NASDAQ:EQ

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.